Drugs / ISIS-GCGRRx
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02824003 | Apr → Dec 2016 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02583919 | Sep 2015 → Dec 2016 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01885260 | Jul 2013 → May 2014 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2014-06-16 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes ionis.com ↗
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. |
| 2014-05-14 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c in Patients With Type 2 Diabetes ionis.com ↗
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. |
| 2012-12-07 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders ionis.com ↗
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from Phase 1 studies of three drugs, ISIS-PTP1BRx, ISIS-GCGRRx and ISIS-GCCRRx, in development to treat metabolic disorders, including type 2 diabetes. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-06-16 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes ionis.com ↗ |
| 2014-05-14 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c in Patients With Type 2 Diabetes ionis.com ↗ |
| 2012-12-07 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders ionis.com ↗ |
| 2011-11-02 | Ionis Pharmaceuticals | Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes ionis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS-GCGRRX | “The purpose of this study is to evaluate the effect of ISIS 449884 (ISIS-GCGRRX) on Hepatic Lipid and Glycogen Content in patients with Type 2 Diabetes being treated with Metformin.” NCT02824003 ↗ |
| Known as | IONIS-GCGR(Rx) | “Antisense Inhibition of Glucagon Receptor by IONIS-GCGR(Rx) Improves Type 2” PMID 30765435 ↗ Feb 2019 |
| Action | Inhibit | “IONIS-GCGRRx is a potent inhibitor of hepatic glucagon receptor expression” PMID 30765435 ↗ Feb 2019 |
| Modality | Antisense oligonucleotide | “2'-O-methoxyethyl antisense oligonucleotide” PMID 30765435 ↗ Feb 2019 |
| Route | Subcutaneous | “patients with type 2 diabetes on metformin received weekly subcutaneous injections of IONIS-GCGRRx” PMID 30765435 ↗ Feb 2019 |
| Target | GCGR | “targeting the glucagon receptor (GCGR)” PMID 30765435 ↗ Feb 2019 |